-
24-11-2016, 09:34 AM
#15151
Originally Posted by winner69
But OldGuy - you missed this bit -
Total Laboratory Throughput of 5,622 tests, up 72% on pcp due to growing commercial sales and new User Programmes
you should buy some then, winner
-
24-11-2016, 09:36 AM
#15152
Originally Posted by OldGuy
you should buy some then, winner
Maybe when they get to 'tens of thousands' .......a month
“ At the top of every bubble, everyone is convinced it's not yet a bubble.”
-
24-11-2016, 09:37 AM
#15153
For some, enough is never enough
Good results, looking forward to what should be a great 2nd half, for me, the operating cash flows say it all... outflows barely increased as a result of a 232% increase in receipts from revenue and grant income, while laboratory throughput has nearly doubled from 1H16 (but again, these key numbers still won't be good enough)... revenue outgrowing expenses in a big way, and $14.6m cash on hand (who was scaremongering with the capital raising again? )... oh and they are doing tens of thousands of tests a year
Last edited by trader_jackson; 24-11-2016 at 09:38 AM.
-
24-11-2016, 09:39 AM
#15154
Originally Posted by winner69
But OldGuy - you missed this bit -
Total Laboratory Throughput of 5,622 tests, up 72% on pcp due to growing commercial sales and new User Programmes
is 72% more of a little ,equal to alot?
-
24-11-2016, 09:40 AM
#15155
Receivables increased to $6.4m - whatever that means
“ At the top of every bubble, everyone is convinced it's not yet a bubble.”
-
24-11-2016, 09:46 AM
#15156
Member
Originally Posted by trader_jackson
and $14.6m cash on hand (who was scaremongering with the capital raising again? )...
Loss has been $6.4m, $9m, now $11.5m for the last three halves. Do you think $14.6m cash on hand is enough?
-
24-11-2016, 09:47 AM
#15157
Thats a terrible result. Revenue of $3.8m (slowing down) and a loss of $11.5m. Can't last much longer without another cap raise or something....
And then there is the increasing receivables...(from $4m to $6m) mind boggles.
12. GOING CONCERN
While the Company continues to incur operating losses, the Company remains solvent
and continues to meet its debts as they fall due. The cash flows are a critical part of
ensuring the business continues to operate in line with the business strategy adopted
by the Directors. In preparing the financial statements, the Directors have applied the
principles of going concern on the basis that current cash reserves and its ability to
generate cash will be sufficient to meet its debts as they fall due for a minimum of
12 months from signing the financial statements. Given there is uncertainty of future
cash flows at the date of signing these financial statements, a material uncertainty
exists at that date.
Last edited by blackcap; 24-11-2016 at 09:52 AM.
-
24-11-2016, 09:51 AM
#15158
Discounted cap raise @$.30?
-
24-11-2016, 09:53 AM
#15159
Originally Posted by trader_jackson
Good results, looking forward to what should be a great 2nd half, for me, the operating cash flows say it all... outflows barely increased as a result of a 232% increase in receipts from revenue and grant income, while laboratory throughput has nearly doubled from 1H16 (but again, these key numbers still won't be good enough)... revenue outgrowing expenses in a big way, and $14.6m cash on hand (who was scaremongering with the capital raising again? )... oh and they are doing tens of thousands of tests a year
Thats the direction they are heading TJ (cap raising)---Meanwhile USA is in turmoil in terms of making decisions on healthcare
-
24-11-2016, 09:58 AM
#15160
To be fair this is common statement but the message is that they either sell more quickly, reduce costs or ask for more capital.
Tags for this Thread
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Bookmarks